Jenburkt Pharmaceuticals Income Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Operating Revenue	1,687	1,517	1,420	1,367	1,240
Other Revenue	102.99	-	0	-	-
Revenue	1,790	1,517	1,420	1,367	1,240
Revenue Growth (YoY)	18.03%	6.85%	3.82%	10.30%	13.44%
Cost of Revenue	323.26	308.3	313.42	338.6	321.51
Gross Profit	1,467	1,209	1,106	1,029	918.3
Selling, General & Admin	498.82	455.36	424.89	388.07	364.91
Other Operating Expenses	427.93	349.14	350.1	336.35	280.04
Operating Expenses	957.82	831.78	798.38	747.01	663.93
Operating Income	509.32	376.84	307.87	281.88	254.37
Interest Expense	-4.62	-3.8	-2.3	-3	-3.48
Interest & Investment Income	-	53.5	41.8	40.65	44.04
Currency Exchange Gain (Loss)	-	4.93	3.32	7.6	2.45
Other Non Operating Income (Expenses)	-	-0.73	-0.41	0.46	-0.87
EBT Excluding Unusual Items	504.7	430.74	350.28	327.59	296.51
Gain (Loss) on Sale of Investments	-	8.58	1.33	0.04	0.02
Gain (Loss) on Sale of Assets	-	-	-	-	1.84
Other Unusual Items	-39.51	-	-	-	-
Pretax Income	465.19	439.33	351.76	328.65	298.71
Income Tax Expense	117.83	118.72	91.99	82.58	75.74
Net Income	347.36	320.61	259.77	246.07	222.97
Net Income to Common	347.36	320.61	259.77	246.07	222.97
Net Income Growth	8.34%	23.42%	5.57%	10.36%	35.12%
Shares Outstanding (Basic)	4	4	4	5	5
Shares Outstanding (Diluted)	4	4	4	5	5
Shares Change (YoY)	-0.00%	-	-3.34%	-0.52%	-
EPS (Basic)	78.71	72.65	58.86	53.90	48.58
EPS (Diluted)	78.71	72.65	58.86	53.90	48.58
EPS Growth	8.35%	23.42%	9.21%	10.93%	35.12%
Free Cash Flow	128.05	81.92	55.7	149.48	62.17
Free Cash Flow Per Share	29.02	18.56	12.62	32.74	13.55
Dividend Per Share	-	18.000	15.300	14.400	12.000
Dividend Growth	-	17.65%	6.25%	20.00%	17.65%
Gross Margin	81.95%	79.68%	77.92%	75.24%	74.07%
Operating Margin	28.45%	24.84%	21.69%	20.61%	20.52%
Profit Margin	19.40%	21.14%	18.30%	17.99%	17.98%
Free Cash Flow Margin	7.15%	5.40%	3.92%	10.93%	5.01%
EBITDA	540.4	397.4	324.26	298.93	267.14
EBITDA Margin	30.18%	26.20%	22.84%	21.86%	21.55%
D&A For EBITDA	31.08	20.56	16.4	17.05	12.77
EBIT	509.32	376.84	307.87	281.88	254.37
EBIT Margin	28.45%	24.84%	21.69%	20.61%	20.52%
Effective Tax Rate	25.33%	27.02%	26.15%	25.13%	25.36%
Revenue as Reported	1,790	1,584	1,466	1,419	1,289

Source: S&P Global Market Intelligence. Standard template. Financial Sources.